Comparison of NN5401 Versus Insulin Glargine, Both Combin... | NCT01045707

ID	Type	Description
2009-011271-78	EudraCT Number
U1111-1111-7178	Other Identifier	WHO
2009-015839-33	EudraCT Number
U1111-1114-9237	Other Identifier	WHO

Status Module

Oversight Module

Description Module

Label	Type	Description	Intervention Names
IDegAsp OD	Experimental		Drug: insulin degludec/insulin aspart
IGlar OD	Experimental		Drug: insulin glargine

Name	Type	Description	Arm Group Labels	Other Names
insulin degludec/insulin aspart	Drug	Injected s.c. (under the skin) once daily with the breakfast meal. Dose was individually adjusted.	IDegAsp OD

Outcomes Module

Primary Outcomes

Measure	Description	Time Frame
Main Trial (Primary Endpoint): Change in Glycosylated Haemoglobin (HbA1c) After 26 Weeks of Treatment	Change from baseline in HbA1c after 26 weeks of treatment.	Week 0, Week 26
Extension Trial (Primary Endpoint): Rate of Confirmed Hypoglycaemic Episodes	Rate of confirmed hypoglycaemic episodes per 100 patient years of exposure (PYE). Confirmed hypoglycaemic episodes consisted of severe hypoglycaemia as well as minor hypoglycaemic episodes. Severe hypoglycaemic episodes are defined as requiring assistance to administer carbohydrate, glucagon, or other resuscitative actions. Minor hypoglycaemic episodes are defined as able to treat her/himself and plasma glucose below 3.1 mmol/L.	Week 0 to Week 53 + 7 days follow up
Extension Trial (Primary Endpoint): Rate of Nocturnal Confirmed Hypoglycaemic Episodes	Rate of confirmed hypoglycaemic episodes per 100 patient years of exposure (PYE). Confirmed hypoglycaemic episodes consisted of severe hypoglycaemia as well as minor hypoglycaemic episodes. Severe hypoglycaemic episodes are defined as requiring assistance to administer carbohydrate, glucagon, or other resuscitative actions. Minor hypoglycaemic episodes are defined as able to treat her/himself and plasma glucose below 3.1 mmol/L. Nocturnal hypoglycaemic episodes are defined as occurring between 00:01 and 05:59 a.m.	Week 0 to Week 53 + 7 days follow up
Extension Trial (Primary Endpoint): Rate of Treatment Emergent Adverse Events (AEs)	Corresponds to rate of AEs per 100 patient years of exposure. Severity assessed by investigator. Mild:no or transient symptoms, no interference with the subject's daily activities. Moderate: marked symptoms, moderate interference with the subject's daily activities. Severe: considerable interference with the subject's daily activities, unacceptable. Serious AE: AE that at any dose results in any of the following: death, a life-threatening experience, in-subject hospitalisation/prolongation of existing hospitalisation, persistent/significant disability/incapacity/congenital anomaly/birth defect

Secondary Outcomes

Measure	Description	Time Frame
Extension Trial (Secondary Endpoint): Change in Glycosylated Haemoglobin (HbA1c) After 52 Weeks of Treatment	Change from baseline in HbA1c after 52 weeks of treatment.	Week 0, Week 53
Main Trial (Secondary Endpoint): Mean of 9-point Self Measured Plasma Glucose Profile (SMPG) at Week 26

Eligibility Module

Name	Affiliation	Role
Global Clinical Registry (GCR, 1452)	Novo Nordisk A/S	Study Director

Facility	Status	City	State	ZIP	Country	Contacts
Novo Nordisk Investigational Site		Birmingham	Alabama	35233	United States
Novo Nordisk Investigational Site

References Module

Citations

PubMed Identifier	Type	Citation	Retractions
27760129	Result	Kumar A, Franek E, Wise J, Niemeyer M, Mersebach H, Simo R. Efficacy and Safety of Once-Daily Insulin Degludec/Insulin Aspart versus Insulin Glargine (U100) for 52 Weeks in Insulin-Naive Patients with Type 2 Diabetes: A Randomized Controlled Trial. PLoS One. 2016 Oct 19;11(10):e0163350. doi: 10.1371/journal.pone.0163350. eCollection 2016.
35044568

Label	URL
Clinical Trials at Novo Nordisk	View source

Results Section

Participant Flow Module

Arm/Group Information

ID	Title	Description
FG000	IDegAsp OD	Insulin degludec/insulin aspart (IDegAsp) was given subcutaneously (s.c.) once daily (OD) in combination with subject's pre-trial treatment of metformin. IDegAsp was given with breakfast for 26 weeks in the main period and with either breakfast or with the largest meal for another 26 weeks in the extension period.
FG001

Baseline Characteristics Module

Outcome Measures Module

Adverse Events Module

More Info Module

Arm/Group Information

ID	Title	Description
BG000	IDegAsp OD	Insulin degludec/insulin aspart (IDegAsp) was given subcutaneously (s.c.) once daily (OD) in combination with subject's pre-trial treatment of metformin. IDegAsp was given with breakfast for 26 weeks in the main period and with either breakfast or with the largest meal for another 26 weeks in the extension period.
BG001	IGlar OD	Insulin glargine (IGlar) was given subcutaneously (s.c.) once daily (OD) according to approved labelling in combination with subject's pre-trial treatment of metformin. IGlar was given for 52 weeks (26 weeks in main period and 26 weeks in extension period).
BG002	Total	Total of all reporting groups

Baseline Measures

Title

Description

Population Description

Parameter Type

Dispersion Type

Unit of Measure

Calculate Percentage

Denominator Units Selected

Denominators

Classes

Age, Continuous

Mean

Standard Deviation

years

Title

Denominators

Categories

Title	Measurements
	BG00057.4± 9.0 BG00156.4± 9.2 BG00256.9± 9.1

Gender

Count of Participants

Participants

Title

Denominators

Categories

Title	Measurements
Female	BG000141 BG001127 BG002

Glycosylated haemoglobin (HbA1c)

Mean

Standard Deviation

percentage of glycosylated haemoglobin

Title

Denominators

Categories

Title	Measurements
	BG0008.9± 1.0 BG0018.9± 0.9 BG002

Fasting plasma glucose (FPG)

Mean

Standard Deviation

mmol/L

Title

Denominators

Categories

Title	Measurements
	BG00010.1± 2.9 BG00110.4± 2.8 BG002

Type

Title

Description

Population Description

Reporting Status

Anticipated Posting Date

Parameter Type

Dispersion Type

Unit of Measure

Calculate Percentage

Time Frame

Units Analyzed

Denominator Units Selected

Arm/Group Information

Denominators

Classes

Analyses

Primary

Main Trial (Primary Endpoint): Change in Glycosylated Haemoglobin (HbA1c) After 26 Weeks of Treatment

Change from baseline in HbA1c after 26 weeks of treatment.

The full analysis set (FAS) included all randomised subjects and missing data were imputed using last observation carried forward (LOCF). One subject was excluded from FAS because the subject was randomised in error and was not dosed.

Posted

Mean

Standard Deviation

percentage of glycosylated haemoglobin

Week 0, Week 26

ID	Title	Description
OG000	IDegAsp OD	Insulin degludec/insulin aspart (IDegAsp) was given subcutaneously (s.c.) once daily (OD) in combination with subject's pre-trial treatment of metformin. IDegAsp was given with breakfast for 26 weeks in the main period and with either breakfast or with the largest meal for another 26 weeks in the extension period.
OG001	IGlar OD	Insulin glargine (IGlar) was given subcutaneously (s.c.) once daily (OD) according to approved labelling in combination with subject's pre-trial treatment of metformin. IGlar was given for 52 weeks (26 weeks in main period and 26 weeks in extension period).

Units	Counts
Participants	OG000266 OG001263

Title

Denominators

Categories

Title	Measurements
	OG000-1.65± 1.28 OG001-1.72± 1.17

Secondary

Extension Trial (Secondary Endpoint): Change in Glycosylated Haemoglobin (HbA1c) After 52 Weeks of Treatment

Change from baseline in HbA1c after 52 weeks of treatment.

Posted

Mean

Standard Deviation

percentage of glycosylated haemoglobin

Week 0, Week 53

ID	Title	Description
OG000	IDegAsp OD	Insulin degludec/insulin aspart (IDegAsp) was given subcutaneously (s.c.) once daily (OD) in combination with subject's pre-trial treatment of metformin. IDegAsp was given with breakfast for 26 weeks in the main period and with either breakfast or with the largest meal for another 26 weeks in the extension period.
OG001	IGlar OD	Insulin glargine (IGlar) was given subcutaneously (s.c.) once daily (OD) according to approved labelling in combination with subject's pre-trial treatment of metformin. IGlar was given for 52 weeks (26 weeks in main period and 26 weeks in extension period).

Units	Counts

Secondary

Main Trial (Secondary Endpoint): Mean of 9-point Self Measured Plasma Glucose Profile (SMPG) at Week 26

Mean of SMPG at 26 weeks of treatment. Plasma glucose measured: before breakfast, 90 minutes after start of breakfast, before lunch, 90 minutes after start of lunch, before dinner, 90 minutes after start of dinner, bedtime, at 4 am and before breakfast.

Posted

Mean

Standard Deviation

mmol/L

Week 26

ID	Title	Description
OG000	IDegAsp OD	Insulin degludec/insulin aspart (IDegAsp) was given subcutaneously (s.c.) once daily (OD) in combination with subject's pre-trial treatment of metformin. IDegAsp was given with breakfast for 26 weeks in the main period and with either breakfast or with the largest meal for another 26 weeks in the extension period.
OG001	IGlar OD	Insulin glargine (IGlar) was given subcutaneously (s.c.) once daily (OD) according to approved labelling in combination with subject's pre-trial treatment of metformin. IGlar was given for 52 weeks (26 weeks in main period and 26 weeks in extension period).

Primary

Extension Trial (Primary Endpoint): Rate of Confirmed Hypoglycaemic Episodes

Rate of confirmed hypoglycaemic episodes per 100 patient years of exposure (PYE). Confirmed hypoglycaemic episodes consisted of severe hypoglycaemia as well as minor hypoglycaemic episodes. Severe hypoglycaemic episodes are defined as requiring assistance to administer carbohydrate, glucagon, or other resuscitative actions. Minor hypoglycaemic episodes are defined as able to treat her/himself and plasma glucose below 3.1 mmol/L.

The safety analysis set included all subjects who received at least one dose of the investigational product or its comparator.

Posted

Number

Episodes/100 years of patient exposure

Week 0 to Week 53 + 7 days follow up

ID	Title	Description
OG000	IDegAsp OD	Insulin degludec/insulin aspart (IDegAsp) was given subcutaneously (s.c.) once daily (OD) in combination with subject's pre-trial treatment of metformin. IDegAsp was given with breakfast for 26 weeks in the main period and with either breakfast or with the largest meal for another 26 weeks in the extension period.
OG001	IGlar OD	Insulin glargine (IGlar) was given subcutaneously (s.c.) once daily (OD) according to approved labelling in combination with subject's pre-trial treatment of metformin. IGlar was given for 52 weeks (26 weeks in main period and 26 weeks in extension period).

Primary

Extension Trial (Primary Endpoint): Rate of Nocturnal Confirmed Hypoglycaemic Episodes

The safety analysis set included all subjects who received at least one dose of the investigational product or its comparator.

Posted

Number

Episodes/100 years of patient exposure

Week 0 to Week 53 + 7 days follow up

ID	Title	Description
OG000	IDegAsp OD	Insulin degludec/insulin aspart (IDegAsp) was given subcutaneously (s.c.) once daily (OD) in combination with subject's pre-trial treatment of metformin. IDegAsp was given with breakfast for 26 weeks in the main period and with either breakfast or with the largest meal for another 26 weeks in the extension period.
OG001	IGlar OD	Insulin glargine (IGlar) was given subcutaneously (s.c.) once daily (OD) according to approved labelling in combination with subject's pre-trial treatment of metformin. IGlar was given for 52 weeks (26 weeks in main period and 26 weeks in extension period).

Primary

Extension Trial (Primary Endpoint): Rate of Treatment Emergent Adverse Events (AEs)

Corresponds to rate of AEs per 100 patient years of exposure. Severity assessed by investigator. Mild:no or transient symptoms, no interference with the subject's daily activities. Moderate: marked symptoms, moderate interference with the subject's daily activities. Severe: considerable interference with the subject's daily activities, unacceptable. Serious AE: AE that at any dose results in any of the following: death, a life-threatening experience, in-subject hospitalisation/prolongation of existing hospitalisation, persistent/significant disability/incapacity/congenital anomaly/birth defect

The safety analysis set included all subjects who received at least one dose of the investigational product or its comparator.

Posted

Number

Events/100 years of patient exposure

Week 0 to Week 53 + 7 days follow up

ID	Title	Description
OG000	IDegAsp OD	Insulin degludec/insulin aspart (IDegAsp) was given subcutaneously (s.c.) once daily (OD) in combination with subject's pre-trial treatment of metformin. IDegAsp was given with breakfast for 26 weeks in the main period and with either breakfast or with the largest meal for another 26 weeks in the extension period.
OG001	IGlar OD	Insulin glargine (IGlar) was given subcutaneously (s.c.) once daily (OD) according to approved labelling in combination with subject's pre-trial treatment of metformin. IGlar was given for 52 weeks (26 weeks in main period and 26 weeks in extension period).

Arm/Groups

ID	Title	Description	Deaths (Affected)	Deaths (At Risk)	Serious Events (Affected)	Serious Events (At Risk)	Other Events (Affected)	Other Events (At Risk)
EG000	IDegAsp OD	Insulin degludec/insulin aspart (IDegAsp) was given subcutaneously (s.c.) once daily (OD) in combination with subject's pre-trial treatment of metformin. IDegAsp was given with breakfast for 26 weeks in the main period and with either breakfast or with the largest meal for another 26 weeks in the extension period.			30	265	88	265
EG001	IGlar OD	Insulin glargine (IGlar) was given subcutaneously (s.c.) once daily (OD) according to approved labelling in combination with subject's pre-trial treatment of metformin. IGlar was given for 52 weeks (26 weeks in main period and 26 weeks in extension period).			15	261	79	261

Serious Adverse Events

Term	Organ System	Source Vocabulary	Assessment Type	Statistical Information
Acute myocardial infarction	Cardiac disorders	MedDRA V 13.1 & 14.0	Systematic Assessment	EG0002 events2 affected265 at risk EG0010 events0 affected261 at risk
Coronary artery disease	Cardiac disorders	MedDRA V 13.1 & 14.0	Systematic Assessment	EG0001 events1 affected265 at risk EG0010 events0 affected261 at risk
Ileus paralytic	Gastrointestinal disorders	MedDRA V 13.1 & 14.0	Systematic Assessment	EG0000 events0 affected265 at risk EG0011 events1 affected261 at risk
Death	General disorders	MedDRA V 13.1 & 14.0	Systematic Assessment	EG0001 events1 affected265 at risk EG0010 events0 affected261 at risk
Non-cardiac chest pain	General disorders	MedDRA V 13.1 & 14.0	Systematic Assessment	EG0001 events1 affected265 at risk EG0010 events0 affected261 at risk
Bile duct stone	Hepatobiliary disorders	MedDRA V 13.1 & 14.0	Systematic Assessment	EG0000 events0 affected265 at risk EG0011 events1 affected261 at risk
Cholelithiasis	Hepatobiliary disorders	MedDRA V 13.1 & 14.0	Systematic Assessment	EG0001 events1 affected265 at risk EG0011 events1 affected261 at risk
Bronchitis	Infections and infestations	MedDRA V 13.1 & 14.0	Systematic Assessment	EG0001 events1 affected265 at risk EG0010 events0 affected261 at risk
Gastroenteritis	Infections and infestations	MedDRA V 13.1 & 14.0	Systematic Assessment	EG0001 events1 affected265 at risk EG0010 events0 affected261 at risk
Osteomyelitis	Infections and infestations	MedDRA V 13.1 & 14.0	Systematic Assessment	EG0001 events1 affected265 at risk EG0010 events0 affected261 at risk
Skull fracture	Injury, poisoning and procedural complications	MedDRA V 13.1 & 14.0	Systematic Assessment	EG0000 events0 affected265 at risk EG0011 events1 affected261 at risk
Diabetic ketoacidosis	Metabolism and nutrition disorders	MedDRA V 13.1 & 14.0	Systematic Assessment	EG0001 events1 affected265 at risk EG0010 events0 affected261 at risk
Hypoglycaemic unconsciousness	Metabolism and nutrition disorders	MedDRA V 13.1 & 14.0	Systematic Assessment	EG0002 events2 affected265 at risk EG0011 events1 affected261 at risk
Metastases to liver	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	MedDRA V 13.1 & 14.0	Systematic Assessment	EG0001 events1 affected265 at risk EG0010 events0 affected261 at risk
Cerebrovascular insufficiency	Nervous system disorders	MedDRA V 13.1 & 14.0	Systematic Assessment	EG0001 events1 affected265 at risk EG0010 events0 affected261 at risk
Dizziness	Nervous system disorders	MedDRA V 13.1 & 14.0	Systematic Assessment	EG0001 events1 affected265 at risk EG0010 events0 affected261 at risk
Haemorrhagic stroke	Nervous system disorders	MedDRA V 13.1 & 14.0	Systematic Assessment	EG0001 events1 affected265 at risk EG0010 events0 affected261 at risk
Renal colic	Renal and urinary disorders	MedDRA V 13.1 & 14.0	Systematic Assessment	EG0000 events0 affected265 at risk EG0011 events1 affected261 at risk
Benign prostatic hyperplasia	Reproductive system and breast disorders	MedDRA V 13.1 & 14.0	Systematic Assessment	EG0001 events1 affected265 at risk EG0010 events0 affected261 at risk
Laryngeal inflammation	Respiratory, thoracic and mediastinal disorders	MedDRA V 13.1 & 14.0	Systematic Assessment	EG0001 events1 affected265 at risk EG0010 events0 affected261 at risk
Respiratory distress	Respiratory, thoracic and mediastinal disorders	MedDRA V 13.1 & 14.0	Systematic Assessment	EG0000 events0 affected265 at risk EG0011 events1 affected261 at risk
Thrombophlebitis	Vascular disorders	MedDRA V 13.1 & 14.0	Systematic Assessment	EG0003 events1 affected265 at risk EG0010 events0 affected261 at risk
Thrombosis	Vascular disorders	MedDRA V 13.1 & 14.0	Systematic Assessment	EG0001 events1 affected265 at risk EG0010 events0 affected261 at risk
Hypertension	Vascular disorders	MedDRA V 13.1 & 14.0	Systematic Assessment	EG0001 events1 affected265 at risk EG0010 events0 affected261 at risk
Pulmonary embolism	Respiratory, thoracic and mediastinal disorders	MedDRA V 13.1 & 14.0	Systematic Assessment	EG0000 events0 affected265 at risk EG0011 events1 affected261 at risk
Endometrial hyperplasia	Reproductive system and breast disorders	MedDRA V 13.1 & 14.0	Systematic Assessment	EG0000 events0 affected265 at risk EG0011 events1 affected261 at risk
Subarachnoid haemorrhage	Nervous system disorders	MedDRA V 13.1 & 14.0	Systematic Assessment	EG0000 events0 affected265 at risk EG0011 events1 affected261 at risk
Ischaemic stroke	Nervous system disorders	MedDRA V 13.1 & 14.0	Systematic Assessment	EG0000 events0 affected265 at risk EG0011 events1 affected261 at risk
Diabetic neuropathy	Nervous system disorders	MedDRA V 13.1 & 14.0	Systematic Assessment	EG0000 events0 affected265 at risk EG0011 events1 affected261 at risk
Brain oedema	Nervous system disorders	MedDRA V 13.1 & 14.0	Systematic Assessment	EG0000 events0 affected265 at risk EG0011 events1 affected261 at risk
Polymyalgia Rheumatica	Musculoskeletal and connective tissue disorders	MedDRA V 13.1 & 14.0	Systematic Assessment	EG0001 events1 affected265 at risk EG0010 events0 affected261 at risk
Osteoarthritis	Musculoskeletal and connective tissue disorders	MedDRA V 13.1 & 14.0	Systematic Assessment	EG0001 events1 affected265 at risk EG0010 events0 affected261 at risk
Hypoglycaemia	Metabolism and nutrition disorders	MedDRA V 13.1 & 14.0	Systematic Assessment	EG0000 events0 affected265 at risk EG0011 events1 affected261 at risk
Hyperglycaemia	Metabolism and nutrition disorders	MedDRA V 13.1 & 14.0	Systematic Assessment	EG0001 events1 affected265 at risk EG0010 events0 affected261 at risk
Road traffic accident	Injury, poisoning and procedural complications	MedDRA V 13.1 & 14.0	Systematic Assessment	EG0000 events0 affected265 at risk EG0011 events1 affected261 at risk
Sepsis	Infections and infestations	MedDRA V 13.1 & 14.0	Systematic Assessment	EG0000 events0 affected265 at risk EG0011 events1 affected261 at risk
Necrotising fasciitis	Infections and infestations	MedDRA V 13.1 & 14.0	Systematic Assessment	EG0000 events0 affected265 at risk EG0011 events1 affected261 at risk
Cellulitis	Infections and infestations	MedDRA V 13.1 & 14.0	Systematic Assessment	EG0001 events1 affected265 at risk EG0010 events0 affected261 at risk
Cholecystitis acute	Hepatobiliary disorders	MedDRA V 13.1 & 14.0	Systematic Assessment	EG0001 events1 affected265 at risk EG0011 events1 affected261 at risk
Haemorrhoidal haemorrhage	Gastrointestinal disorders	MedDRA V 13.1 & 14.0	Systematic Assessment	EG0000 events0 affected265 at risk EG0011 events1 affected261 at risk
Gastric ulcer	Gastrointestinal disorders	MedDRA V 13.1 & 14.0	Systematic Assessment	EG0001 events1 affected265 at risk EG0010 events0 affected261 at risk
Duodenal Ulcer Haemorrhage	Gastrointestinal disorders	MedDRA V 13.1 & 14.0	Systematic Assessment	EG0002 events2 affected265 at risk EG0010 events0 affected261 at risk
Dental caries	Gastrointestinal disorders	MedDRA V 13.1 & 14.0	Systematic Assessment	EG0001 events1 affected265 at risk EG0010 events0 affected261 at risk
Cataract	Eye disorders	MedDRA V 13.1 & 14.0	Systematic Assessment	EG0000 events0 affected265 at risk EG0011 events1 affected261 at risk
Myocardial infarction	Cardiac disorders	MedDRA V 13.1 & 14.0	Systematic Assessment	EG0002 events2 affected265 at risk EG0010 events0 affected261 at risk
Coronary artery occlusion	Cardiac disorders	MedDRA V 13.1 & 14.0	Systematic Assessment	EG0001 events1 affected265 at risk EG0010 events0 affected261 at risk
Cardiac failure congestive	Cardiac disorders	MedDRA V 13.1 & 14.0	Systematic Assessment	EG0001 events1 affected265 at risk EG0010 events0 affected261 at risk

Other Adverse Events

Term	Organ System	Source Vocabulary	Assessment Type	Statistical Information
Nasopharyngitis	Infections and infestations	MedDRA V 13.1 & 14.0	Systematic Assessment	EG00047 events36 affected265 at risk EG00151 events35 affected261 at risk
Headache	Nervous system disorders	MedDRA V 13.1 & 14.0	Systematic Assessment	EG00019 events16 affected265 at risk EG00120 events11 affected261 at risk
Hypertension	Vascular disorders	MedDRA V 13.1 & 14.0	Systematic Assessment	EG00023 events20 affected265 at risk EG00112 events11 affected261 at risk
Back Pain	Musculoskeletal and connective tissue disorders	MedDRA V 13.1 & 14.0	Systematic Assessment	EG00024 events16 affected265 at risk EG00115 events11 affected261 at risk
Upper Respiratory Tract Infection	Infections and infestations	MedDRA V 13.1 & 14.0	Systematic Assessment	EG00017 events15 affected265 at risk EG00118 events12 affected261 at risk
Bronchitis	Infections and infestations	MedDRA V 13.1 & 14.0	Systematic Assessment	EG00015 events14 affected265 at risk EG00111 events10 affected261 at risk
Diarrhoea	Gastrointestinal disorders	MedDRA V 13.1 & 14.0	Systematic Assessment	EG00020 events13 affected265 at risk EG00116 events15 affected261 at risk

ID	Term
D003920	Diabetes Mellitus
D003924	Diabetes Mellitus, Type 2

ID	Term
D044882	Glucose Metabolism Disorders
D008659	Metabolic Diseases
D009750	Nutritional and Metabolic Diseases
D004700	Endocrine System Diseases

ID	Term
D049528	Insulin, Long-Acting
D061385	Insulins
D010187	Pancreatic Hormones
D036361	Peptide Hormones
D006728	Hormones
D006730	Hormones, Hormone Substitutes, and Hormone Antagonists
D010455	Peptides
D000602	Amino Acids, Peptides, and Proteins

ID	Term
C578220	insulin degludec, insulin aspart drug combination
D000069036	Insulin Glargine